Literature DB >> 29363179

HLA-DR+ NK cells are mostly characterized by less mature phenotype and high functional activity.

Sofya A Erokhina1, Maria A Streltsova1, Leonid M Kanevskiy1, William G Telford2, Alexander M Sapozhnikov1, Elena I Kovalenko1.   

Abstract

NK cells change their phenotype and functional characteristics during activation. In this work, we searched for a relationship of HLA-DR expression with differentiation stages and functional activity of NK cells ex vivo and stimulated in vitro with IL-2 challenged with gene modified feeder K562 cells expressing membrane-bound IL-21 (K562-mbIL21). This stimulation technique has been described for NK cell expansion in clinical use. We have observed that HLA-DR expression in freshly isolated circulating NK cells was mostly associated with less differentiated CD56bright CD57- cells, although in some individuals it could also be found in terminally differentiated CD57+ cells. Ex vivo HLA-DR+ NK cells possessed better capacity to produce IFN-γ in response to cytokine stimulation compared to their HLA-DR- counterparts. In vitro activation with IL-2 and K562-mbIL21 induces an increase in HLA-DR-positive NK cell proportion, again mostly among CD56bright CD57- NK cells. This happened in particular due to appearance of HLA-DR+ expression de novo in HLA-DR-negative cells. Acquired in vitro HLA-DR expression was associated with NK cell proliferation activity, more intense cytokine-induced IFN-γ production, increased degranulation toward feeder cells, and higher expression of CD86 and NKG2D. Thus, stimulation with IL-2/K562-mbIL21 causes a significant phenotype and functional shift during NK cell activation and expansion.
© 2017 Australasian Society for Immunology Inc.

Entities:  

Keywords:  HLA-DR; Human NK cells; IL-2; IL-21; NK cell activation

Mesh:

Substances:

Year:  2017        PMID: 29363179      PMCID: PMC8063572          DOI: 10.1111/imcb.1032

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  45 in total

1.  Long-term proliferation of functional human NK cells, with conversion of CD56(dim) NK cells to a CD56 (bright) phenotype, induced by carcinoma cells co-expressing 4-1BBL and IL-12.

Authors:  Alexander C Dowell; Kimberley A Oldham; Rupesh I Bhatt; Steven P Lee; Peter F Searle
Journal:  Cancer Immunol Immunother       Date:  2011-10-22       Impact factor: 6.968

2.  Association of STAT1, STAT3 and STAT5 proteins with the IL-2 receptor involves different subdomains of the IL-2 receptor beta chain.

Authors:  M Delespine-Carmagnat; G Bouvier; J Bertoglio
Journal:  Eur J Immunol       Date:  2000-01       Impact factor: 5.532

3.  Significant NK cell activation associated with decreased cytolytic function in peripheral blood of HIV-1-infected patients.

Authors:  Manuela Fogli; Paola Costa; Giuseppe Murdaca; Maurizio Setti; Maria Cristina Mingari; Lorenzo Moretta; Alessandro Moretta; Andrea De Maria
Journal:  Eur J Immunol       Date:  2004-08       Impact factor: 5.532

4.  NK cell terminal differentiation: correlated stepwise decrease of NKG2A and acquisition of KIRs.

Authors:  Vivien Béziat; Benjamin Descours; Christophe Parizot; Patrice Debré; Vincent Vieillard
Journal:  PLoS One       Date:  2010-08-06       Impact factor: 3.240

5.  Interleukin-21 activates human natural killer cells and modulates their surface receptor expression.

Authors:  Kresten Skak; Klaus Stensgaard Frederiksen; Dorthe Lundsgaard
Journal:  Immunology       Date:  2007-11-14       Impact factor: 7.397

Review 6.  Present Yourself! By MHC Class I and MHC Class II Molecules.

Authors:  Kenneth L Rock; Eric Reits; Jacques Neefjes
Journal:  Trends Immunol       Date:  2016-09-07       Impact factor: 16.687

7.  Replicative potential of human natural killer cells.

Authors:  Hiroyuki Fujisaki; Harumi Kakuda; Chihaya Imai; Charles G Mullighan; Dario Campana
Journal:  Br J Haematol       Date:  2009-03-26       Impact factor: 6.998

Review 8.  Human natural killer cells.

Authors:  Michael A Caligiuri
Journal:  Blood       Date:  2008-08-01       Impact factor: 22.113

9.  Preparation of Cytokine-activated NK Cells for Use in Adoptive Cell Therapy in Cancer Patients: Protocol Optimization and Therapeutic Potential.

Authors:  Monique M van Ostaijen-ten Dam; Henk-Jan Prins; Gerharda H Boerman; Carly Vervat; Daniela Pende; Hein Putter; Arjan Lankester; Maarten J D van Tol; Jaap J Zwaginga; Marco W Schilham
Journal:  J Immunother       Date:  2016 Feb-Mar       Impact factor: 4.456

10.  CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts.

Authors:  Antoni Chan; Deng-Li Hong; Ann Atzberger; Simon Kollnberger; Andrew D Filer; Christopher D Buckley; Andrew McMichael; Tariq Enver; Paul Bowness
Journal:  J Immunol       Date:  2007-07-01       Impact factor: 5.422

View more
  17 in total

1.  Panoramic comparison between NK cells in healthy and cancerous liver through single-cell RNA sequencing.

Authors:  Huan Liu; Ronghua Zhao; Rongrong Qin; Haoyu Sun; Qiang Huang; Lianxin Liu; Zhigang Tian; Björn Nashan; Cheng Sun; Rui Sun
Journal:  Cancer Biol Med       Date:  2022-07-21       Impact factor: 5.347

2.  CD56dim CD57- NKG2C+ NK cells retaining proliferative potential are possible precursors of CD57+ NKG2C+ memory-like NK cells.

Authors:  Polina A Kobyzeva; Maria A Streltsova; Sofya A Erokhina; Leonid M Kanevskiy; William G Telford; Alexander M Sapozhnikov; Elena I Kovalenko
Journal:  J Leukoc Biol       Date:  2020-09-15       Impact factor: 6.011

3.  Analysis of NK cell clones obtained using interleukin-2 and gene-modified K562 cells revealed the ability of "senescent" NK cells to lose CD57 expression and start expressing NKG2A.

Authors:  Maria A Streltsova; Sofya A Erokhina; Leonid M Kanevskiy; Dean A Lee; William G Telford; Alexander M Sapozhnikov; Elena I Kovalenko
Journal:  PLoS One       Date:  2018-12-05       Impact factor: 3.240

4.  Propofol improves the function of natural killer cells from the peripheral blood of patients with esophageal squamous cell carcinoma.

Authors:  Min Zhou; Junchao Dai; Yu Zhou; Jian Wu; Tao Xu; Denglian Zhou; Xiaobin Wang
Journal:  Exp Ther Med       Date:  2018-05-08       Impact factor: 2.447

5.  Human Cytomegalovirus Antigen Presentation by HLA-DR+ NKG2C+ Adaptive NK Cells Specifically Activates Polyfunctional Effector Memory CD4+ T Lymphocytes.

Authors:  Marcel Costa-García; Michelle Ataya; Manuela Moraru; Carlos Vilches; Miguel López-Botet; Aura Muntasell
Journal:  Front Immunol       Date:  2019-04-03       Impact factor: 7.561

6.  Cirrhosis Hampers Early and Rapid Normalization of Natural Killer Cell Phenotype and Function in Hepatitis C Patients Undergoing Interferon-Free Therapy.

Authors:  Elena Perpiñán; Sofía Pérez-Del-Pulgar; María-Carlota Londoño; Zoe Mariño; Concepción Bartres; Patricia González; Mireia García-López; Elisa Pose; Sabela Lens; Mala K Maini; Xavier Forns; George Koutsoudakis
Journal:  Front Immunol       Date:  2020-02-25       Impact factor: 7.561

7.  A novel population of memory-activated natural killer cells associated with low parasitaemia in Plasmodium falciparum-exposed sickle-cell trait children.

Authors:  Claire Loiseau; Ogobara K Doumbo; Boubacar Traore; Jamie L Brady; Carla Proietti; Karina P de Sousa; Peter D Crompton; Denise L Doolan
Journal:  Clin Transl Immunology       Date:  2020-04-02

8.  Regulation of NK-Cell Function by HLA Class II.

Authors:  Annika Niehrs; Marcus Altfeld
Journal:  Front Cell Infect Microbiol       Date:  2020-02-18       Impact factor: 5.293

9.  Mass Cytometry Studies of Patients With Autoimmune Endocrine Diseases Reveal Distinct Disease-Specific Alterations in Immune Cell Subsets.

Authors:  Louise Magnusson; Hugo Barcenilla; Mikael Pihl; Sophie Bensing; Daniel Espes; Per-Ola Carlsson; Rosaura Casas
Journal:  Front Immunol       Date:  2020-02-21       Impact factor: 7.561

10.  Toward a Better Understanding of Bioassays for the Development of Biopharmaceuticals by Exploring the Structure-Antibody-Dependent Cellular Cytotoxicity Relationship in Human Primary Cells.

Authors:  Sébastien Wieckowski; Cécile Avenal; Arturo V Orjalo; Daniel Gygax; Florian Cymer
Journal:  Front Immunol       Date:  2020-10-29       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.